Royalty Pharma to pick up MS drug for more than $2.8B
March 01, 2017
Biotechnology | Research Triangle Park, NC | Acquisition
Royalty Pharma has agreed to acquire royalty rights to the multiple sclerosis drug Tysabri from Perrigo (NYSE: PRGO) for up to $2.85 billion, comprising $2.2 billion in cash and up to $650 million in potential payments (as much as $250 million in 2018 and $400 million in 2020) based on future sales. Perrigo closed Tuesday's trading down nearly 12%.